drugset

drugset / Trial / NCT00675350

Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

NCT00675350 ↗

Phase 1 Completed 12 enrolled ChemGenex Pharmaceuticals

NaSingle-groupOpen-label

Summary

PK Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

Timeline

Start: 2008-04
Primary completion: 2008-09
Completion: 2009-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Omacetaxine	Unknown	1.25 mg/m2	Subcutaneous

Indications